Compass Pathways
Nasdaq-listed biotech pioneering psilocybin-based treatments for mental health conditions, notably treatment-resistant depression.
Compass Pathways Investor RelationsCOMPASS Pathways plc (Nasdaq: CMPS) is a London-headquartered biotechnology company founded in 2016 by George Goldsmith, Ekaterina Malievskaia, and Lars Christian Wilde. Originally structured as a nonprofit, it converted to a for-profit model in 2016 and in 2020 became the first psychedelic medicine company listed on the NASDAQ.
The company's lead asset is COMP360, a synthetic psilocybin treatment for treatment-resistant depression (TRD). COMP360 holds Breakthrough Therapy designation from the U.S. FDA and the UK's Innovative Licensing and Access Pathway (ILAP) designation — positioning it as a potentially first-in-class therapy.
Compass reports two Phase 3 trials with highly statistically significant positive results for COMP360 in TRD, describing it as the first classic psychedelic to consistently achieve such outcomes with a generally well-tolerated safety profile. The company is regarded as the largest in the psychedelic medicine industry.
Notable backers include Peter Thiel (Founders Fund), Christian Angermayer, and Mike Novogratz, alongside institutional investors such as Perceptive Advisors. Innovations in synthetic psychedelic-assisted therapy, regulatory strategy, and clinical-scale manufacturing are directly central to Compass Pathways' business model and competitive position.